Dimeric Quinacrine Derivatives As Autophagy Inhibitors For Cancer Therapy
US-2021070712-A1 · Mar 11, 2021 · US
1,4-bis(3-aminopropyl)piperazine derivative and its use
US10017476B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10017476-B2 |
| Application number | US-201615558921-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 16, 2016 |
| Priority date | Mar 16, 2015 |
| Publication date | Jul 10, 2018 |
| Grant date | Jul 10, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the compound having Formula (I) or pharmaceutically acceptable salts or solvates thereof, and its use in treating and/or preventing a Tauopathy.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound having Formula I or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant.
Assignees
Inventors
Classifications
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Anti-Parkinson drugs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10017476B2 cover?
- The present invention relates to the compound having Formula (I) or pharmaceutically acceptable salts or solvates thereof, and its use in treating and/or preventing a Tauopathy.
- Who is the assignee on this patent?
- Inserm Institut National De La Sante Et De La Res Medicale, Centre Hospitalier Regional Et Univ De Lille Chru, Univ Lille Ii Droit & Sante, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07D219/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).